Regeneron Pharmaceuticals Net Income vs. Price To Earning

REGN Stock  USD 778.00  10.10  1.32%   
Based on Regeneron Pharmaceuticals' profitability indicators, Regeneron Pharmaceuticals is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in January. Profitability indicators assess Regeneron Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Net Income  
First Reported
1991-06-30
Previous Quarter
1.4 B
Current Value
1.3 B
Quarterly Volatility
488.4 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Regeneron Pharmaceuticals' Days Sales Outstanding is very stable compared to the past year. As of the 7th of December 2024, Operating Cash Flow Sales Ratio is likely to grow to 0.37, while Price To Sales Ratio is likely to drop 6.79. At this time, Regeneron Pharmaceuticals' Interest Income is very stable compared to the past year. As of the 7th of December 2024, Net Interest Income is likely to grow to about 362.9 M, though Accumulated Other Comprehensive Income is likely to grow to (76.9 M).
For Regeneron Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Regeneron Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Regeneron Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Regeneron Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Regeneron Pharmaceuticals over time as well as its relative position and ranking within its peers.
  

Regeneron Pharmaceuticals' Revenue Breakdown by Earning Segment

Check out Your Equity Center.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.298
Earnings Share
40.46
Revenue Per Share
128.691
Quarterly Revenue Growth
0.106
Return On Assets
0.0741
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Regeneron Pharmaceuticals Price To Earning vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Regeneron Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Regeneron Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Regeneron Pharmaceuticals is rated second in net income category among its peers. It is rated below average in price to earning category among its peers . The ratio of Net Income to Price To Earning for Regeneron Pharmaceuticals is about  254,906,512 . At this time, Regeneron Pharmaceuticals' Net Income is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Regeneron Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Regeneron Pharmaceuticals' Earnings Breakdown by Geography

Regeneron Price To Earning vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Regeneron Pharmaceuticals

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
3.95 B
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Regeneron Pharmaceuticals

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
15.51 X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Regeneron Price To Earning Comparison

Regeneron Pharmaceuticals is currently under evaluation in price to earning category among its peers.

Regeneron Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Regeneron Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Regeneron Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Regeneron Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Regeneron Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-80.9 M-76.9 M
Operating IncomeB4.2 B
Net IncomeB4.2 B
Income Before Tax4.2 B4.4 B
Total Other Income Expense Net152.2 M159.8 M
Income Tax Expense245.7 M169.5 M
Net Income Applicable To Common SharesB5.2 B
Net Income From Continuing OpsB2.2 B
Non Operating Income Net Other206.2 M216.5 M
Interest Income417.7 M438.6 M
Net Interest Income345.6 M362.9 M
Change To Netincome608.9 M639.3 M
Net Income Per Share 37.05  38.91 
Income Quality 1.16  0.63 
Net Income Per E B T 0.94  1.10 

Regeneron Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Regeneron Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Regeneron Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Regeneron Pharmaceuticals' important profitability drivers and their relationship over time.

Use Regeneron Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Regeneron Pharmaceuticals Pair Trading

Regeneron Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.
The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Regeneron Pharmaceuticals position

In addition to having Regeneron Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run ESG Investing Thematic Idea Now

ESG Investing
ESG Investing Theme
Sustainable investments that promote the conservation of the natural world, social resposibility, freindly employees policies and strong governance. The ESG Investing theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ESG Investing Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Check out Your Equity Center.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
To fully project Regeneron Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Regeneron Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Regeneron Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Regeneron Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Regeneron Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Regeneron Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Regeneron Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.